PL378057A1 - Zastosowanie enancjomerów (1S, 2R) milnacypranu do wytwarzania leku - Google Patents
Zastosowanie enancjomerów (1S, 2R) milnacypranu do wytwarzania lekuInfo
- Publication number
- PL378057A1 PL378057A1 PL378057A PL37805704A PL378057A1 PL 378057 A1 PL378057 A1 PL 378057A1 PL 378057 A PL378057 A PL 378057A PL 37805704 A PL37805704 A PL 37805704A PL 378057 A1 PL378057 A1 PL 378057A1
- Authority
- PL
- Poland
- Prior art keywords
- active
- serotonin
- noradrenaline
- capture
- enantiomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0301849A FR2851163B1 (fr) | 2003-02-14 | 2003-02-14 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament |
US10/453,574 US7005452B2 (en) | 2003-02-14 | 2003-06-03 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Publications (2)
Publication Number | Publication Date |
---|---|
PL378057A1 true PL378057A1 (pl) | 2006-02-20 |
PL219671B1 PL219671B1 (pl) | 2015-06-30 |
Family
ID=32929266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL378057A PL219671B1 (pl) | 2003-02-14 | 2004-02-16 | Zastosowanie enancjomeru (1S, 2R) milnacypranu do wytwarzania leku |
Country Status (20)
Country | Link |
---|---|
US (2) | US7074833B2 (pl) |
EP (2) | EP1601349B1 (pl) |
KR (1) | KR101185322B1 (pl) |
AT (1) | ATE401872T1 (pl) |
AU (1) | AU2004216452B2 (pl) |
BR (1) | BRPI0407256A (pl) |
CA (1) | CA2514948C (pl) |
DE (1) | DE602004015257D1 (pl) |
DK (1) | DK1601349T3 (pl) |
ES (1) | ES2310715T3 (pl) |
HK (1) | HK1079117A1 (pl) |
MA (1) | MA27655A1 (pl) |
MX (1) | MXPA05008652A (pl) |
NO (1) | NO333987B1 (pl) |
NZ (1) | NZ541733A (pl) |
PL (1) | PL219671B1 (pl) |
PT (1) | PT1601349E (pl) |
RU (1) | RU2317817C2 (pl) |
SI (1) | SI1601349T1 (pl) |
WO (1) | WO2004075886A1 (pl) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
WO2008031928A1 (fr) * | 2006-09-14 | 2008-03-20 | Pierre Fabre Medicament | Utilisation du milnacipran pour diminuer les proprietes recompensantes de l'alcool pendant ou apres un traitement de sevrage alcoolique |
CN101195583B (zh) | 2006-12-04 | 2012-07-04 | 四川抗菌素工业研究所有限公司 | 一种光学纯米那普仑及其盐的制备方法 |
WO2009023820A1 (en) * | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination |
EP2110129A1 (en) * | 2008-04-18 | 2009-10-21 | Pierre Fabre Medicament | Use of enantiomer (1S, 2R) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients |
US20090270688A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting a combination treatment |
US20100100507A1 (en) * | 2008-09-04 | 2010-04-22 | United Parcel Service Of America, Inc. | Determining Vehicle Visit Costs To A Geographic Area |
CA2779711C (en) * | 2009-11-06 | 2016-11-01 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
WO2011088331A1 (en) * | 2010-01-14 | 2011-07-21 | Forest Laboratories Holdings Limited | Stable dosage forms of levomilnacipran |
WO2011158249A1 (en) * | 2010-06-16 | 2011-12-22 | Glenmark Generics Limited | Process for preparation of milnacipran intermediate and its use in preparation of pure milnacipran |
US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
EP2699539B1 (en) * | 2011-04-21 | 2019-03-06 | Emory University | Cyclopropyl derivatives and methods of use |
FR2978350B1 (fr) | 2011-07-28 | 2013-11-08 | Pf Medicament | Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu |
US10583128B2 (en) * | 2011-09-06 | 2020-03-10 | Curna, Inc. | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
AU2013257706A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
AU2013257742A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
EP2852569B1 (en) | 2012-05-23 | 2020-10-14 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
NZ701832A (en) | 2012-05-23 | 2016-08-26 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
CA2873029A1 (en) | 2012-09-08 | 2014-03-13 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
US10379551B2 (en) | 2013-07-10 | 2019-08-13 | Crowdcomfort, Inc. | Systems and methods for providing augmented reality-like interface for the management and maintenance of building systems |
US10070280B2 (en) | 2016-02-12 | 2018-09-04 | Crowdcomfort, Inc. | Systems and methods for leveraging text messages in a mobile-based crowdsourcing platform |
US11394462B2 (en) | 2013-07-10 | 2022-07-19 | Crowdcomfort, Inc. | Systems and methods for collecting, managing, and leveraging crowdsourced data |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
SG11201705524SA (en) | 2015-01-06 | 2017-08-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of inflammation and pain |
CN111620807A (zh) * | 2019-02-27 | 2020-09-04 | 北京万全德众医药生物技术有限公司 | 一种盐酸左旋米那普仑杂质的制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
FR2746314B1 (fr) | 1996-03-25 | 1998-06-12 | Pf Medicament | Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee |
FR2752732B1 (fr) | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
FR2759290B1 (fr) | 1997-02-13 | 2004-06-18 | Pf Medicament | Minalcipran pour le traitement de l'incontinence urinaire |
FR2759906B1 (fr) | 1997-02-21 | 2004-06-04 | Pf Medicament | Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques |
UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
WO2001062236A2 (en) | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US6635675B2 (en) * | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
CA2475763A1 (en) * | 2002-02-12 | 2003-08-21 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
CA2479350A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
EP1499309A4 (en) * | 2002-04-24 | 2008-05-28 | Cypress Bioscience Inc | PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES |
JP2006504795A (ja) | 2002-10-03 | 2006-02-09 | サイプレス バイオサイエンス, インコーポレイテッド | 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬 |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
WO2004105690A2 (en) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Treatment of chronic pain associated with drug or radiation therapy |
-
2004
- 2004-02-16 DE DE602004015257T patent/DE602004015257D1/de not_active Expired - Lifetime
- 2004-02-16 DK DK04711387T patent/DK1601349T3/da active
- 2004-02-16 WO PCT/FR2004/000347 patent/WO2004075886A1/fr active Application Filing
- 2004-02-16 RU RU2005128548/15A patent/RU2317817C2/ru active
- 2004-02-16 PL PL378057A patent/PL219671B1/pl unknown
- 2004-02-16 ES ES04711387T patent/ES2310715T3/es not_active Expired - Lifetime
- 2004-02-16 SI SI200430810T patent/SI1601349T1/sl unknown
- 2004-02-16 NZ NZ541733A patent/NZ541733A/en not_active IP Right Cessation
- 2004-02-16 MX MXPA05008652A patent/MXPA05008652A/es active IP Right Grant
- 2004-02-16 PT PT04711387T patent/PT1601349E/pt unknown
- 2004-02-16 EP EP04711387A patent/EP1601349B1/fr not_active Expired - Lifetime
- 2004-02-16 AT AT04711387T patent/ATE401872T1/de active
- 2004-02-16 KR KR1020057015077A patent/KR101185322B1/ko active IP Right Grant
- 2004-02-16 EP EP07123564A patent/EP1908461B9/fr not_active Expired - Lifetime
- 2004-02-16 CA CA2514948A patent/CA2514948C/fr not_active Expired - Lifetime
- 2004-02-16 AU AU2004216452A patent/AU2004216452B2/en not_active Expired
- 2004-02-16 BR BR0407256-1A patent/BRPI0407256A/pt not_active Application Discontinuation
- 2004-03-22 US US10/805,940 patent/US7074833B2/en not_active Expired - Lifetime
-
2005
- 2005-08-12 MA MA28435A patent/MA27655A1/fr unknown
- 2005-09-12 NO NO20054228A patent/NO333987B1/no unknown
- 2005-09-20 US US11/231,236 patent/US20060014837A1/en not_active Abandoned
-
2006
- 2006-01-13 HK HK06100644A patent/HK1079117A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1908461B9 (fr) | 2011-08-31 |
EP1908461A1 (fr) | 2008-04-09 |
US7074833B2 (en) | 2006-07-11 |
PT1601349E (pt) | 2008-10-27 |
BRPI0407256A (pt) | 2006-01-31 |
SI1601349T1 (sl) | 2008-10-31 |
DK1601349T3 (da) | 2008-10-27 |
RU2317817C2 (ru) | 2008-02-27 |
KR20050096190A (ko) | 2005-10-05 |
ES2310715T3 (es) | 2009-01-16 |
PL219671B1 (pl) | 2015-06-30 |
CA2514948A1 (fr) | 2004-09-10 |
ATE401872T1 (de) | 2008-08-15 |
AU2004216452B2 (en) | 2008-10-16 |
MA27655A1 (fr) | 2005-12-01 |
WO2004075886A1 (fr) | 2004-09-10 |
NO20054228L (no) | 2005-09-12 |
HK1079117A1 (en) | 2006-03-31 |
EP1908461B1 (fr) | 2011-03-16 |
US20040259953A1 (en) | 2004-12-23 |
AU2004216452A1 (en) | 2004-09-10 |
CA2514948C (fr) | 2013-04-02 |
KR101185322B1 (ko) | 2012-09-21 |
NO333987B1 (no) | 2013-11-04 |
MXPA05008652A (es) | 2005-10-18 |
US20060014837A1 (en) | 2006-01-19 |
RU2005128548A (ru) | 2006-01-20 |
EP1601349B1 (fr) | 2008-07-23 |
DE602004015257D1 (de) | 2008-09-04 |
EP1601349A1 (fr) | 2005-12-07 |
NZ541733A (en) | 2009-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1079117A1 (en) | Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament | |
IL201038A0 (en) | Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament | |
AP2001002252A0 (en) | Monoamine reuptake inhibitors for treatment of CNS disorders. | |
ATE506059T1 (de) | Therapie zur behandlung der überaktiven blase | |
AP2002002481A0 (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors. | |
BRPI0413821A (pt) | composto ou seus sais farmaceuticamente aceitáveis, composição farmacêutica, inibidor de gsk-3, e, agente para tratar ou prevenir um doença mediada por gsk-3 | |
EA200500776A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОР ОБРАТНОГО ЗАХВАТА СЕРОТОНИНА И/ИЛИ НОРЭПИНЕФРИНА, И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ФУНКЦИИ МОЧЕВОГО ПУЗЫРЯ | |
IL173062A0 (en) | Substituted 2-aminotetralin for the treatment of depression | |
RU2008127882A (ru) | Лечение пищевода барретта | |
RU2007126638A (ru) | Профилактическое или терапевтическое средство для лечения расстройства сна | |
DK1322305T3 (da) | Anvendelse af R-arylpropionsyrer til fremstilling af lægemidler til behandling af lidelser af rheumatisk natur | |
TW200507853A (en) | Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | |
WO2008085872A8 (en) | Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders | |
DK1455770T3 (da) | Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser | |
SE0203778D0 (sv) | A new oral immediated release dosage form | |
ATE506348T1 (de) | Neue benzoylpiperidinverbindungen | |
TW200504016A (en) | Inhibitors of monoamine uptake | |
HUP0301863A2 (hu) | Szorongásos megbetegedések gyógyítása szelektív norepinefrin visszavétel gátló hatású vegyületekkel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISD | Decisions on discontinuance of the proceedings of a derived patent or utility model |
Ref document number: 402987 |